How a country wiped out sleeping sickness – the ‘frightening’ disease that requires a deadly drug to treat

How a country wiped out sleeping sickness – the ‘frightening’ disease that requires a deadly drug to treat
Share:
How a country wiped out sleeping sickness – the ‘frightening’ disease that requires a deadly drug to treat
Author: Luke Alsford
Published: Feb, 23 2025 10:00

Before you know it you are awake all night, chucking books across rooms and laughing uncontrollably. This is what happens when sleeping sickness is left untreated, and before it inevitably kills you. The disease was once rampant across Guinea and required a deadly arsenic drug to treat, but with a medical miracle the illness was declared eliminated from the country at the end of January.

 [Vases of melarsoprol (or arsobal)]
Image Credit: Metro [Vases of melarsoprol (or arsobal)]

Dr Wilfriend Mutombo used to be the only doctor in a village of 11,000 ridden with sleeping sickness infections. He would have to inject the terrifying arsenic drug, called melarsoprol, into the veins of patients to try save them from certain death. The drug itself was so dangerous it killed one in 20 people who took it.

 [Dr Mariame Camara, DNDi Investigator, National Sleeping Sickness Program and Dr Wilfried Mutombo, the Head of Clinical Operations for DNDi in the DRC, with acoziborole pills at the Dubreka Clinical Trial site]
Image Credit: Metro [Dr Mariame Camara, DNDi Investigator, National Sleeping Sickness Program and Dr Wilfried Mutombo, the Head of Clinical Operations for DNDi in the DRC, with acoziborole pills at the Dubreka Clinical Trial site]

‘Just thinking of melarsoprol gave us shivers. The injections were painful,’ Mutombo told Metro. He is now the head of clinical operations for Drugs and Neglected Diseases initiative (DNDi) in the Democratic Republic of the Congo (DRC). ‘In addition to the pain, I was more afraid of the famous and terrible reaction to the drug,’ he said.

 [The Diagnostic Manager at the National Programme of Neglected Tropical Diseases, Guinea, is examining blood samples taken from people suspected of having sleeping sickness. Today a Sleeping Sickness Programme team is in in Douprou to test the entire village for sleeping sickness, following the identification of a case]
Image Credit: Metro [The Diagnostic Manager at the National Programme of Neglected Tropical Diseases, Guinea, is examining blood samples taken from people suspected of having sleeping sickness. Today a Sleeping Sickness Programme team is in in Douprou to test the entire village for sleeping sickness, following the identification of a case]

‘Unfortunately I lost two patients this way when I worked in the village. ‘Both were in their twenties. Each time, it was a painful experience for me as a doctor: I had to endure the look in the family’s eyes that meant, without saying it, “You killed our son”.

 [A box of NECT being transported on boat]
Image Credit: Metro [A box of NECT being transported on boat]

‘Patients don’t come to hospital to die, they come to be cured or to get relief. ‘Fortunately what I just described is history now.’. Sleeping sickness, medically known as Human African trypanosomiasis, is a parasite spread through the bite of tsetse flies, who thrived in the swampy mangrove of Guinea’s coast.

 [A lone tiny trap sways in the breeze near Kéréba. In the distance the city of Conakry -but this settlement is so remote it is only reachable by boat. “The bugs are disappearing since we received the tiny targets,” villagers said. In the salt mining camp of Kéréba. The skyline of Conakry is visible from the tiny settlement of Kéréba but it is only reachable by boat from the port of Dubreka. This small, temporary settlement is emblematic of the challenges the Sleeping Sickness Programme of Guinea and the IRD faced in reaching small, often mobile groups of people moving in and out of the mangrove.]
Image Credit: Metro [A lone tiny trap sways in the breeze near Kéréba. In the distance the city of Conakry -but this settlement is so remote it is only reachable by boat. “The bugs are disappearing since we received the tiny targets,” villagers said. In the salt mining camp of Kéréba. The skyline of Conakry is visible from the tiny settlement of Kéréba but it is only reachable by boat from the port of Dubreka. This small, temporary settlement is emblematic of the challenges the Sleeping Sickness Programme of Guinea and the IRD faced in reaching small, often mobile groups of people moving in and out of the mangrove.]

The historic disease, first picked up in colonial times, resurged in the 1990s with deadly results in Guinea and the DRC. ‘Sleeping sickness is quite frightening to see,’ James Arkinstall, Communications and Advocacy Director at DNDi told Metro. ‘People think they are cursed. They become quite scared of it.

 [Setting up tiny traps in a coastal mangrove channel. On the far left Angela Ceballos Caro, PhD student at Centro Nacional de Microbiología (CNM) in Madrid, Spain, who is visiting Guinea to conduct research on sleeping sickness and other vector-borne diseases. In the beige hat, Bruno Bucheton Research Fellow, Research Institute for Development, with the grey hat Dr Moīse Kagbadouno, National Sleeping Sickness Program Entomologist, Guinea, and in the blue hat Jean-Mathieu Bart, Research Fellow, Research Institute for Development. Vector control of the tsetse fly is one of the main pillars of the Guinean sleeping sickness elimination programme and a huge factor in the national success story of combatting sleeping sickness.]
Image Credit: Metro [Setting up tiny traps in a coastal mangrove channel. On the far left Angela Ceballos Caro, PhD student at Centro Nacional de Microbiología (CNM) in Madrid, Spain, who is visiting Guinea to conduct research on sleeping sickness and other vector-borne diseases. In the beige hat, Bruno Bucheton Research Fellow, Research Institute for Development, with the grey hat Dr Moīse Kagbadouno, National Sleeping Sickness Program Entomologist, Guinea, and in the blue hat Jean-Mathieu Bart, Research Fellow, Research Institute for Development. Vector control of the tsetse fly is one of the main pillars of the Guinean sleeping sickness elimination programme and a huge factor in the national success story of combatting sleeping sickness.]

‘If you don’t get treatment, it is almost always fatal. You will eventually end up falling into a coma.’. Arkinstall added: ‘When the tsetse fly bites, you get infected. If symptoms appear it is easy to confuse with malaria. ‘After a while it crosses the blood-brain barrier and then symptoms become more specific.

 [a pill of fexinidazole]
Image Credit: Metro [a pill of fexinidazole]

‘You become very aggressive. You don’t sleep at night and start sleeping during the day. ‘We met one person who was shaking and laughing uncontrollably.’. The disease ‘decimated populations in the 1960s’, with the toxic melarsoprol drug being all doctor’s had to combat the illness until 2009.

 [The Diagnostic Manager at the National Programme of Neglected Tropical Diseases, Guinea, is examining blood samples taken from people suspected of having sleeping sickness. Today a Sleeping Sickness Programme team is in in Douprou to test the entire village for sleeping sickness, following the identification of a case]
Image Credit: Metro [The Diagnostic Manager at the National Programme of Neglected Tropical Diseases, Guinea, is examining blood samples taken from people suspected of having sleeping sickness. Today a Sleeping Sickness Programme team is in in Douprou to test the entire village for sleeping sickness, following the identification of a case]

It was then doctors replaced melarsoprol with a new drug called NECT. The safer treatment, however, was cumbersome, heavy and required ten days in hospital attached to a drip. Society was beginning to get to grips with sleeping sickness. Researchers were experimenting with catching infected tsetse flies and doctors were having success testing for the disease.

 [Dr Wilfried Mutombo, the Head of Clinical Operations for DNDi in the DRC, with acoziborole pills at the Dubreka Clinical Trial site in Guinea]
Image Credit: Metro [Dr Wilfried Mutombo, the Head of Clinical Operations for DNDi in the DRC, with acoziborole pills at the Dubreka Clinical Trial site in Guinea]

Then came Ebola. Guinea was at the epicentre of the deadly disease’s outbreak in West Africa from 2013 and over 3,000 people died from the highly contagious illness. Arkinstall said: ‘People were burning down clinics, there was so little trust in the health system.

‘All of the health system was pretty much put on freeze. Nobody was going to the health centre anymore. Doctors and nurses were getting attacked.’. As cases of one illness skyrocketed, so did cases of sleeping sickness. But of the chaos of Ebola came a ray of hope.

Scientists noticed that areas which persisted with an innovative new fly trapping technique had far more success keeping caseloads of sleeping sickness down. The blue ‘flag’ traps attract the tsetse flies close to waterline and kill them within minutes.

Nearly 15,000 of these traps have now been deployed annually in high-risk areas since 2016. Just as fly trapping was taking off, a miracle new drug also entered the scene. Called fexinidazole, the medicine had been sitting untouched in a drug library for decades when it was rediscovered by DNDi scientists.

Requiring only a course of pills over ten days outside of hospital, trials showed it was 91% effective and it was approved by the European Medicines Agency in 2018. A highly effective public testing campaign also helped to keep on top of new outbreaks.

‘Doctors will alert the village that they are going to test in that area and everyone will turn up,’ Arkinstall said. ‘People are willing to get tested. It is a well oiled machine. ‘Although it is a scary disease people now know the treatment is there and it is free.’.

These three-pronged strategy led to the moment Guineans had been waiting for. On January 29 2025, the country announced sleeping sickness had been eliminated as a public health problem. This means the country now sees less than 1 case per 10,000 people in at-risk areas. As few as 12 cases were diagnosed in 2024.

Share:

More for You

Top Followed